Education
About Us
Working with TipRanks
Follow Us
Clinuvel Pharmaceuticals Limited (CLVLF)
OTHER OTC:CLVLF
RESEARCH TOOLSreports
Total Valuation
Clinuvel Pharmaceuticals Limited has a market cap or net worth of $334.39M. The enterprise value is $597.55M.
Market Cap$334.39M
Enterprise Value$597.55M
Share Statistics
Clinuvel Pharmaceuticals Limited has 50.12M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding50.12M
Owned by Insiders0.03%
Owned by Instutions
Financial Efficiency
Clinuvel Pharmaceuticals Limited’s return on equity (ROE) is 0.18 and return on invested capital (ROIC) is 16.75%.
Return on Equity (ROE)17.55%
Return on Assets (ROA)15.42%
Return on Invested Capital (ROIC)16.75%
Return on Capital Employed (ROCE)23.87%
Revenue Per Employee$∞
Profits Per Employee$∞
Employee Count0
Asset Turnover0.38
Inventory Turnover0.73
Valuation Ratios
The current PE Ratio of Clinuvel Pharmaceuticals Limited is 21.35. Clinuvel Pharmaceuticals Limited’s PEG ratio is 1.32.
PE Ratio21.35
PS Ratio8.63
PB Ratio3.75
Price to Fair Value3.75
Price to FCF24.17
Price to Operating Cash Flow20.54
PEG Ratio1.32
Income Statement
In the last 12 months, Clinuvel Pharmaceuticals Limited had revenue of $91.02M and earned $38.78M in profits. Earnings per share was $0.77.
Revenue$91.02M
Gross Profit$82.68M
Operating Income$49.10M
Pretax Income$57.81M
Net Income$38.78M
EBITDA51.73M
Earnings Per Share (EPS)0.77
Cash Flow
In the last 12 months, operating cash flow was $23.83M and capital expenditures -$332.53K, giving a free cash flow of $23.49M billion.
Operating Cash Flow$23.83M
Free Cash Flow$23.49M
Free Cash Flow per Share$0.47
Dividends & Yields
Clinuvel Pharmaceuticals Limited pays an annual dividend of $0.03, resulting in a dividend yield of 0.49%
Dividend Per Share$0.03
Dividend Yield0.49%
Payout Ratio6.46%
Free Cash Flow Yield4.14%
Earnings Yield4.68%
Stock Price Statistics
Beta0.39
52-Week Price Change-29.34%
50-Day Moving Average7.31
200-Day Moving Average8.62
Relative Strength Index (RSI)33.22
Average Volume (3m)40.00
Important Dates
Clinuvel Pharmaceuticals Limited upcoming earnings date is Sep 2, 2025, TBA.
Last Earnings DateFeb 26, 2025
Next Earnings DateSep 2, 2025
Ex-Dividend DateSep 5, 2024
Financial Position
Clinuvel Pharmaceuticals Limited as a current ratio of 8.81, with Debt / Equity ratio of <0.01
Current Ratio8.81
Quick Ratio8.39
Debt to Market Cap0.00
Net Debt to EBITDA-3.25
Interest Coverage Ratio11.03
Taxes
In the past 12 months, Clinuvel Pharmaceuticals Limited has paid $19.03M in taxes.
Income Tax$19.03M
Effective Tax Rate29.68%
Enterprise Valuation
Clinuvel Pharmaceuticals Limited EV to EBITDA ratio is 10.27, with an EV/FCF ratio of 18.36.
EV to Sales6.55
EV to EBITDA10.27
EV to Free Cash Flow18.36
EV to Operating Cash Flow15.60
Balance Sheet
Clinuvel Pharmaceuticals Limited has $198.22M in cash and marketable securities with $715.38K in debt, giving a net cash position of -$197.51M billion.
Cash & Marketable Securities$198.22M
Total Debt$715.38K
Net Cash-$197.51M
Net Cash Per Share-$3.94
Tangible Book Value Per Share$4.07
Margins
Gross margin is 91.23%, with operating margin of 55.74%, and net profit margin of 40.41%.
Gross Margin91.23%
Operating Margin55.74%
Pretax Margin57.47%
Net Profit Margin40.41%
EBITDA Margin63.82%
EBIT Margin62.52%
Analyst Forecast
The average price target for Clinuvel Pharmaceuticals Limited is $19.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$19.25
Price Target Upside186.46%
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast
EPS Growth Forecast